DCMD
MCID: MCL027
MIFTS: 51

Macular Dystrophy, Dominant Cystoid (DCMD)

Categories: Eye diseases, Genetic diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Macular Dystrophy, Dominant Cystoid

MalaCards integrated aliases for Macular Dystrophy, Dominant Cystoid:

Name: Macular Dystrophy, Dominant Cystoid 57 13
Cystoid Macular Edema 12 6 15
Autosomal Dominant Cystoid Macular Edema 58 70
Cystoid Macular Dystrophy 57 58
Macular Edema, Cystoid 57 70
Dcmd 57 58
Cystoid Macular Dystrophy; Cymd 57
Familial Macular Edema 58
Macular Retinal Edema 70
Macular Edema 44
Cymd 57
Mddc 57

Characteristics:

Orphanet epidemiological data:

58
cystoid macular dystrophy
Inheritance: Autosomal dominant; Prevalence: <1/1000000 (Worldwide); Age of onset: Childhood;

OMIM®:

57 (Updated 05-Apr-2021)
Inheritance:
autosomal dominant (7p21-p15)


HPO:

31
macular dystrophy, dominant cystoid:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 58  
Rare eye diseases


External Ids:

Disease Ontology 12 DOID:4447
OMIM® 57 153880
MeSH 44 D008269
NCIt 50 C34794
SNOMED-CT 67 193387007
ICD10 via Orphanet 33 H35.5
Orphanet 58 ORPHA75381
MedGen 41 C0024440
UMLS 70 C0024440 C0271051 C0730317

Summaries for Macular Dystrophy, Dominant Cystoid

OMIM® : 57 Dominant cystoid macular dystrophy (DCMD) is a progressive retinal dystrophy characterized primarily by early-onset cystoid fluid collections in the neuroretina (summary by Saksens et al., 2015). (153880) (Updated 05-Apr-2021)

MalaCards based summary : Macular Dystrophy, Dominant Cystoid, also known as cystoid macular edema, is related to bestrophinopathy, autosomal recessive and vitreoretinochoroidopathy, and has symptoms including edema and peau d'orange. An important gene associated with Macular Dystrophy, Dominant Cystoid is CYMD (Cystoid Macular Dystrophy), and among its related pathways/superpathways are Phototransduction and Metabolism of fat-soluble vitamins. The drugs Dorzolamide and Dipivefrin have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and retina, and related phenotypes are strabismus and edema

Related Diseases for Macular Dystrophy, Dominant Cystoid

Diseases related to Macular Dystrophy, Dominant Cystoid via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 445)
# Related Disease Score Top Affiliating Genes
1 bestrophinopathy, autosomal recessive 32.2 RPE65 CRB1 BEST1 ABCA4
2 vitreoretinochoroidopathy 32.1 RPE65 BEST1 ABCA4
3 vitreoretinopathy, neovascular inflammatory 32.1 VEGFA RPE65 CRYAA CAPN5
4 cataract 31.3 VEGFA RHO CRYAA BEST1 ACE
5 microvascular complications of diabetes 5 31.1 VEGFA RHO CRYAA ACE
6 retinal detachment 31.1 VEGFA RS1 RHO CAPN5
7 iritis 31.0 VEGFA ACE
8 severe nonproliferative diabetic retinopathy 31.0 VEGFA ACE
9 macular holes 31.0 VEGFA RS1 RPE65 CRYAA
10 iridocyclitis 30.9 VEGFA ACE
11 branch retinal artery occlusion 30.8 VEGFA CRYAA
12 central retinal artery occlusion 30.8 VEGFA CRYAA
13 neuroretinitis 30.7 RCVRN CAPN5 ACE
14 exudative vitreoretinopathy 1 30.6 VEGFA RHO CRYAA
15 open-angle glaucoma 30.6 VEGFA RHO CRYAA ACE
16 retinal vascular disease 30.5 VEGFA RHO CRYAA ACE
17 retinal artery occlusion 30.5 VEGFA CRYAA ACE
18 neovascular glaucoma 30.5 VEGFA RS1 CRYAA CAPN5
19 toxic maculopathy 30.5 NR2E3 ABCA4
20 posterior scleritis 30.5 VEGFA ACE
21 chorioretinitis 30.5 VEGFA CRB1 ACE ABCA4
22 hypertensive retinopathy 30.4 VEGFA ACE
23 keratitis, hereditary 30.4 VEGFA CRYAA BEST1
24 background diabetic retinopathy 30.4 VEGFA ACE
25 choroiditis 30.3 VEGFA ACE ABCA4
26 glaucoma, primary open angle 30.2 VEGFA RHO CRYAA ABCA4
27 retinal telangiectasia 30.2 VEGFA CRB1
28 pseudopapilledema 30.1 RPE65 CRB1
29 leukocoria 30.1 RS1 CRYAA
30 nonsyndromic retinitis pigmentosa 30.1 USH2A MAK BEST1 ABCA4
31 yemenite deaf-blind hypopigmentation syndrome 30.0 VEGFA USH2A RPE65 RHO ABCA4
32 optic disk drusen 30.0 RPGR RHO CRB1
33 autoimmune uveitis 29.9 RPE65 CRYAA CAPN5
34 coats disease 29.9 VEGFA RS1 RHO CRB1
35 macular retinal edema 29.8 VEGFA RHO CRYAA CRB1 BEST1 ACE
36 vitreoretinal dystrophy 29.8 RS1 NR2E3 CRYAA CAPN5
37 nanophthalmos 29.7 RPE65 RHO NR2E3 CRB1 BEST1
38 cancer-associated retinopathy 29.7 VEGFA TULP1 RHO RCVRN
39 uveal disease 29.6 VEGFA RPE65 RHO CRYAA ACE
40 retinitis pigmentosa 1 29.6 RHO PDE6A NR2E3 CRYAA
41 retinal perforation 29.5 VEGFA RS1 RPE65 CRYAA CAPN5
42 myopia 29.5 VEGFA RPGR RHO CRYAA
43 enhanced s-cone syndrome 29.4 RPGR RPE65 RHO NR2E3
44 exudative vitreoretinopathy 29.3 VEGFA RPGR NR2E3 ABCA4
45 gyrate atrophy of choroid and retina 29.2 RS1 RPGR RPE65 RHO MAK BEST1
46 chorioretinal scar 29.2 VEGFA RHO PDE6A CRB1 BEST1 ABCA4
47 nervous system disease 29.1 VEGFA RHO CRYAA ACE
48 retinitis 29.1 USH2A RPGR RPE65 RHO PDE6A CRB1
49 choroideremia 28.9 USH2A RPGR RPE65 RHO BEST1 ABCA4
50 night blindness 28.7 USH2A RPGR RPE65 RHO NR2E3 CRB1

Graphical network of the top 20 diseases related to Macular Dystrophy, Dominant Cystoid:



Diseases related to Macular Dystrophy, Dominant Cystoid

Symptoms & Phenotypes for Macular Dystrophy, Dominant Cystoid

Human phenotypes related to Macular Dystrophy, Dominant Cystoid:

31 (show all 6)
# Description HPO Frequency HPO Source Accession
1 strabismus 31 HP:0000486
2 edema 31 HP:0000969
3 hypermetropia 31 HP:0000540
4 macular dystrophy 31 HP:0007754
5 cystoid macular edema 31 HP:0011505
6 pericentral retinitis pigmentosa 31 HP:0007947

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Apr-2021)
Eyes:
strabismus
cystoid macular edema
pericentral retinitis pigmentosa
whitish punctate vitreous deposits
moderate to high hyperopia
more
Radiology:
normal electroretinogram

Clinical features from OMIM®:

153880 (Updated 05-Apr-2021)

UMLS symptoms related to Macular Dystrophy, Dominant Cystoid:


edema; peau d'orange

MGI Mouse Phenotypes related to Macular Dystrophy, Dominant Cystoid:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.93 ABCA4 ACE CRB1 NR2E3 PDE6A RHO
2 pigmentation MP:0001186 9.56 ABCA4 BEST1 CRB1 RHO RPE65 RPGR
3 vision/eye MP:0005391 9.47 ABCA4 ACE BEST1 CRB1 NR2E3 PDE6A

Drugs & Therapeutics for Macular Dystrophy, Dominant Cystoid

Drugs for Macular Dystrophy, Dominant Cystoid (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 248)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dorzolamide Approved Phase 4 120279-96-1 3154 5284549
2
Dipivefrin Approved Phase 4 52365-63-6 3105
3
Timolol Approved Phase 4 26839-75-8 33624 5478
4
Povidone-iodine Approved Phase 4 25655-41-8
5
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
6
Bromfenac Approved Phase 4 91714-94-2 60726
7
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
8
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
9
Homatropine Approved Phase 4 87-00-3
10
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
11
Povidone Approved Phase 4 9003-39-8 131751496
12
Iodine Approved, Investigational Phase 4 7553-56-2 807
13
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
14
Travoprost Approved Phase 4 157283-68-6 5282226
15
Bimatoprost Approved, Investigational Phase 4 155206-00-1 5311027
16
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
17
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
18
Phenylephrine Approved Phase 4 59-42-7 6041
19
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
20
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
21
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
22
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
23
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
24
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
25
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
26
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
27
Lactitol Approved, Investigational Phase 4 585-86-4 157355
28
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
29
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
30
Glimepiride Approved Phase 4 93479-97-1 3476
31
Empagliflozin Approved Phase 4 864070-44-0
32
Difluprednate Approved Phase 4 23674-86-4 443936
33
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
34
Cadexomer iodine Experimental Phase 4 94820-09-4
35
Maleic acid Experimental Phase 4 110-16-7 444266
36
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
37 Carboxymethylcellulose Sodium Phase 4
38 Ketorolac Tromethamine Phase 4
39 Neurotransmitter Agents Phase 4
40 Adrenergic Antagonists Phase 4
41 Adrenergic beta-Antagonists Phase 4
42 Antihypertensive Agents Phase 4
43 Adrenergic Agents Phase 4
44 Norgestimate, ethinyl estradiol drug combination Phase 4
45 Anti-Infective Agents Phase 4
46 Pyranoprofen Phase 4
47 Dexamethasone 21-phosphate Phase 4
48 Tocolytic Agents Phase 4
49 Lubricant Eye Drops Phase 4
50 Adrenocorticotropic Hormone Phase 4

Interventional clinical trials:

(show top 50) (show all 781)
# Name Status NCT ID Phase Drugs
1 A Single Arm, Single Dose Study to Evaluate the Effect of Intravitreal Dexamethasone Implant (Ozurdex®) on Hard Exudates of Diabetic Macular Edema Unknown status NCT02399657 Phase 4 Intravitreal dexamethasone 0.7mg implant
2 Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration Unknown status NCT00716586 Phase 4 dorzolamide
3 Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas Unknown status NCT02522897 Phase 4 Ranibizumab
4 Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Unknown status NCT01827722 Phase 4 Ozurdex;Ranibizumab;Combination Ozurdex with Ranibizumab PRN
5 Single Arm, Single Dose Clinical Study to Investigate Efficacy of Treat-and-Extend Regimen of Intravitreal Aflibercept Injection in Diabetic Macular Edema Unknown status NCT02788877 Phase 4 aflibercept
6 Bevacizumab Versus DEX Implant Followed by Bevacizumab in ME Secondary to BRVO Unknown status NCT03892434 Phase 4 Intravitreal bevacizumab and dexamethasone implant Injection
7 A Prospective, Single-Center, Randomized, Double Blind, Double Arm, Comparative Clinical Trial to Compare the Safety and Preliminary Efficacy Between Ranibizumab Monotherapy and Ranibizumab Combined With R:GEN (Selective Retina Therapy) in Clinically Significant Diabetic Macular Edema (a Pilot Study) Unknown status NCT03759860 Phase 4
8 Combined Treatment of Intravitreous Bevacizumab and Triamcinolone for the Treatment or Macular Edema Secondary to Central Retinal Vein Occlusion Unknown status NCT00566761 Phase 4 bevacizumab and triamcinolone
9 POSTERIOR SUB-TENON'S CAPSULE INJECTION OF BEVACIZUMAB FOR TREATMENT OF DIFFUSE DIABETIC MACULAR EDEMA Unknown status NCT00567372 Phase 4 bevacizumab (Sub-tenon´s injection)
10 Effect of Aflibercept (Eylea®) in the Management of Bevacizumab (Avastin®) Resistant Diabetic Macular Edema Unknown status NCT02924987 Phase 4 Aflibercept Injection
11 Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Patients With Persistent Diabetic Macular Edema Following Treatment With Ranibizumab: An Interventional Prospective Study Unknown status NCT02651168 Phase 4
12 Phase 4 Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation Unknown status NCT00804206 Phase 4 bevacizumab;bevacizumab
13 The Effects of Intravitral Ozurdex Implant in DME: Cytokine Change in Aqueous Humor Unknown status NCT03475407 Phase 4 Ozurdex intravitreal injection
14 Intravitreal Diclofenac Versus Intravitreal Ranibizumab for the Treatment of Diabetic Macular Edema. Unknown status NCT03458923 Phase 4 Diclofenac Sodium 0.1 ml containing 500µg;Ranibizumab 0.5 mg Solution for Injection
15 Prospective Trial of Treat and Extend Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: the PLATON Trial Unknown status NCT03405376 Phase 4 Intravitreal aflibercept injection
16 Identifying Ocular and Systemic Biomarkers for Response to Aflibercept in Asian Patients With Centre Involving Diabetic Macular Edema: A Prospective Clinical Trial Unknown status NCT03197480 Phase 4 Aflibercept Injection [Eylea]
17 A Phase 4 Safety Study of IOP Signals in Patients Treated With ILUVIEN® (Fluocinolone Acetonide Intravitreal Implant) 0.19 mg Unknown status NCT02424019 Phase 4 ILUVIEN 0.19 MG
18 Evaluation of an Additional Therapeutic Approach to Diabetic Macular Edema by Combining Standard Therapy (Intravitreal Injection of a VEGF-inhibitor) With Micropulse Diode Laser Treatment in a Randomized, Controlled Proof of Concept Study Unknown status NCT02059772 Phase 4 ranibizumab
19 Phase 4 Study of Intravitreal Aflibercept Injection for Recalcitrant Central Retinal Vein Occlusion Associated Macular Edema Despite Prior Anti-Vascular Endothelial Growth Factor (VEGF) Therapy. (ARChiMEDES) Unknown status NCT01857544 Phase 4 Aflibercept
20 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Macular Edema Post Treatment. Unknown status NCT00563628 Phase 4
21 To Compare the Efficacy of Monotherapy With Anti-Vascular Endothelial Growth Factor (Ranibizumab or Bevacizumab) Versus Combination Therapy With Anti-Vascular Endothelial Growth Factor and End-point-management Grid Laser Photocoagulation for Diabetic Macular Edema Unknown status NCT02462304 Phase 4 ranibizumab;Bevacizumab
22 The Effect of Bevacizumab on Peripheral Retinal Changes as Imaged by Wide -Field Fluorescein Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
23 Pain Control Following Intravitreal Injection Using Topical Nepefanac 0.3% or Pressure Patching: A Prospective, Randomized, Placebo Controlled Trial Unknown status NCT03918590 Phase 4 nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX);Theratears tear drop, (Akron, Ann 111 Arbor, MI)
24 Effect of Nepafenac on Post-operative Cystoid Macular Edema Following Uncomplicated Cataract Surgery Completed NCT00494494 Phase 4 Standard Care;nepafenac
25 A Randomized, Masked Comparison of Topical Ketorolac 0,4% Versus Placebo in Cataract Surgery. Completed NCT01542190 Phase 4 Ketorolac Tromethamine
26 Open Label Macugen for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion Completed NCT00406107 Phase 4 pegaptanib sodium (Macugen)
27 Evaluation of Visual Acuity Improvement of a PRN Regimen Using Ranibizumab for Macular Edema Due to Ischemic and Non- Ischemic Branch Retinal Vein Occlusion. Completed NCT02478515 Phase 4 Ranibizumab
28 Peripheral and Macular Retinal Vascular Perfusion and Leakage Dynamics in Diabetic Macular Edema and Retinal Venous Occlusions During Intravitreal Aflibercept Injection (IAI) Treatment for Retinal Edema: PERMEATE Study Completed NCT02503540 Phase 4 Aflibercept
29 A Randomized, Parallel Group, Masked Clinical Study to Evaluate the Efficacy of Triamcinolone and Bevacizumab Through Intravitreal Injection With Individual or Simultaneous Drugs to Treatment of Diabetic Macular Edema Completed NCT00737971 Phase 4 Bevacizumab intravitreal;Triamcinolone;Triamcinolone + Bevacizumab
30 Randomized Clinical Trial Comparing Prophylactic Nepafenac 0.1% and Ketorolac 0.5% Versus Placebo in Preventing Postoperative Macular Edema After Uncomplicated Phacoemulsification Cataract Extraction (PNK) Completed NCT01395069 Phase 4 Nepafenac 0.1%;Ketorolac 0.5%
31 An Open-label, Multicenter, Phase IV Study of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema in Current Medical Practice Completed NCT01315275 Phase 4 Ranibizumab
32 A Randomized, Double-masked Study With Intraocular Anti-VEGF (Avastin®/Lucentis®) Compared With Intraocular Triamcinolone (Volon A®) in Patients With Clinical Significant Diabetic Macular Edema Completed NCT00682539 Phase 4 Bevacizumab (Avastin);Triamcinolone;Sham
33 Bromfenac BID Plus Prednisolone Acetate BID Versus Bromfenac BID Plus Prednisolone QID for the Prevention of Cystoid Macular Edema and Retinal Thickening Completed NCT00469781 Phase 4 2. Xibrom (Bromfenac);1. Pred Forte
34 Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5% Completed NCT00595543 Phase 4 Bromfenac;Ketorolac;Diclofenac
35 Treat and Extend Versus Dosing Every Eight Weeks With Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema (EVADE Study) Completed NCT02392364 Phase 4 Intravitreal Aflibercept Injection
36 Impact of Different Fluidic Parameters on Development of Cystoid Macular Edema Following Phacoemulsification Completed NCT01385852 Phase 4
37 The Effect of Preoperative Topical Ketorolac 0.45% on Aqueous Cytokine Levels and Macular Thickness in Diabetic and Non Diabetic Patients Undergoing Cataract Surgery Completed NCT02646072 Phase 4 Ketorolac tromethamine ophthalmic solution 0.45%
38 Effect of Drop-less Surgery Compared to Topical NSAID Alone and Combination of Steroid and NSAID on Central Macular Thickness After Cataract Surgery, a Randomized Controlled Trial Completed NCT03383328 Phase 4 NSAID + prednisolone, preoperative;NSAID + prednisolone, postoperative;NSAID, preoperative;NSAID, postoperative;Drop-less surgery
39 Intraoperative Dexamethasone Implant (Ozurdex®) Improves Outcome of Cataract Surgery in Patients With Diabetic Macular Edema Completed NCT01546402 Phase 4 Dexamethasone Drug delivery system (Ozurdex)
40 Comparison of Ketorolac Tromethamine 0.4% and Nepafenac 0.1% for the Prevention of Cystoid Macular Edema After Phacoemulsification: Prospective Randomized Double-masked Study Completed NCT02084576 Phase 4 Nepafenac;Ketorolac
41 A 12-month, Phase IV, Open-label, Randomized, Active Controlled, 2-arm, Multicenter Study Assessing the Efficacy and Safety of Intravitreal Ranibizumab Combined With Grid&Direct Short Pulse Laser Photocoagulation Versus a PRN Ranibizumab Monotherapy in Japanese Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO) Completed NCT02953938 Phase 4
42 Randomized Trial Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With Central Retinal Vein Occlusion With a Treat and Extend Algorithm Completed NCT02274259 Phase 4 Aflibercept;Ranibizumab
43 A Non-Randomized, Open-Label, Single Center Phase 4 Study of the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (Laser, Anti-VEGF) With or Without Intravitreal Corticosteroid Therapy Completed NCT02472366 Phase 4 ILUVIEN
44 Dexamethasone Intravitreal Implant (0.7mg) for the Treatment of Persistent Diabetic Macular Edema Following Intravitreal Anti-Vascular Endothelial Growth Factor Therapy Completed NCT02471651 Phase 4 Dexamethasone intravitreal implant (0.7 mg);Intravitreal anti-VEGF injection
45 A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion Completed NCT01903720 Phase 4 dexamethasone implant
46 A Non-randomised, Open-label, Multicenter Phase 4 Pilot Study on the Effect and Safety of Iluvien® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies With or Without Intravitreal Corticosteroid Therapy (RESPOND) Completed NCT02359526 Phase 4 IlUVIEN
47 Treatment of Exudative Age-Related Macular Degeneration With Aflibercept Combined With Pranoprofen Eye Drops or Nutraceutical Support With Omega-3: A Randomized Trial Completed NCT03355638 Phase 4 Aflibercept Injection [Eylea];Pranoprofen Eyedrops;Omega-3 Supplementation
48 TAHOE: Sustained InTravitreal DexAmetHasone Implant (Ozurdex) for Uveitic Macular Edema Completed NCT01870440 Phase 4 Ozurdex Intravitreal Injection (0.7 mg)
49 NEWTON: A Single-center Open Label Study Evaluating Intravitreal Aflibercept Injection (IAI) for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions Completed NCT01870427 Phase 4 Aflibercept (2.0 mg)
50 Twelve Months Experience With a Dexamethasone-implant for the Treatment of Macular Edema Associated With Retinal Vein Occlusion Completed NCT01767545 Phase 4 Dexamethasone implant;Bevacizumab

Search NIH Clinical Center for Macular Dystrophy, Dominant Cystoid

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Flurbiprofen
Flurbiprofen sodium

Cochrane evidence based reviews: macular edema

Genetic Tests for Macular Dystrophy, Dominant Cystoid

Anatomical Context for Macular Dystrophy, Dominant Cystoid

MalaCards organs/tissues related to Macular Dystrophy, Dominant Cystoid:

40
Eye, Endothelial, Retina, Liver, Brain, Heart

Publications for Macular Dystrophy, Dominant Cystoid

Articles related to Macular Dystrophy, Dominant Cystoid:

(show top 50) (show all 154)
# Title Authors PMID Year
1
Dominant cystoid macular dystrophy. 61 57
25267528 2015
2
Localization of the gene for dominant cystoid macular dystrophy on chromosome 7p. 61 57
8004098 1994
3
Retinal functions in dominant cystoid macular dystrophy (DCMD). 61 57
990013 1976
4
Loci for autosomal dominant retinitis pigmentosa and dominant cystoid macular dystrophy on chromosome 7p are not allelic. 57
8079997 1994
5
Dominantly inherited cystoid macular edema. 57
420475 1979
6
Dominant cystoid macular dystrophy. 57
836665 1977
7
Dominantly inherited cystoid macular edema. 57
970419 1976
8
Ammonia recovery from simulated anaerobic digestate using a two-stage direct contact membrane distillation process. 61
33655629 2021
9
Concentration of Bioactive Phenolic Compounds in Olive Mill Wastewater by Direct Contact Membrane Distillation. 61
33806935 2021
10
DCMD: Distance-based classification using mixture distributions on microbiome data. 61
33711013 2021
11
Carnauba Wax/Halloysite Nanotube with Improved Anti-Wetting and Permeability of Hydrophobic PVDF Membrane via DCMD. 61
33807017 2021
12
Metabolic markers of myocardium insulin resistance in dogs with heart failure. 61
33614430 2021
13
Numerical Investigation of Fabricated MWCNTs/Polystyrene Nanofibrous Membrane for DCMD. 61
33406737 2021
14
Forward osmosis with direct contact membrane distillation using tetrabutylphosphonium p-toluenesulfonate as an effective and safe thermo-recyclable osmotic agent for seawater desalination. 61
33297074 2021
15
Fluorinated silica-modified anti-oil-fouling omniphobic F-SiO2@PES robust membrane for multiple foulants feed in membrane distillation. 61
33297128 2021
16
Selective copper recovery by membrane distillation and adsorption system from synthetic acid mine drainage. 61
32682132 2020
17
Economic Design of Solar-Driven Membrane Distillation Systems for Desalination. 61
33374287 2020
18
Impact of Inorganic Ions and Organic Matter on the Removal of Trace Organic Contaminants by Combined Direct Contact Membrane Distillation-UV Photolysis. 61
33334072 2020
19
Applying Membrane Distillation for the Recovery of Nitrate from Saline Water Using PVDF Membranes Modified as Superhydrophobic Membranes. 61
33255434 2020
20
Modification of PET Ion-Track Membranes by Silica Nanoparticles for Direct Contact Membrane Distillation of Salt Solutions. 61
33143326 2020
21
Design and bio-inspired optimization of direct contact membrane distillation for desalination based on constructal law. 61
33033320 2020
22
Direct contact membrane distillation for effective concentration of perfluoroalkyl substances - Impact of surface fouling and material stability. 61
32544734 2020
23
Low-Temperature Direct Contact Membrane Distillation for the Treatment of Aqueous Solutions Containing Urea. 61
32756324 2020
24
Dye synthetic solution treatment by direct contact membrane distillation using commercial membranes. 61
30569840 2020
25
Macrovoid-Inhibited PVDF Hollow Fiber Membranes via Spinning Process Delay for Direct Contact Membrane Distillation. 61
32469495 2020
26
Macro-corrugated and nano-patterned hierarchically structured superomniphobic membrane for treatment of low surface tension oily wastewater by membrane distillation. 61
32088385 2020
27
Energy efficiency of membrane distillation: Simplified analysis, heat recovery, and the use of waste-heat. 61
32126386 2020
28
Recovery of dissolved methane from anaerobically treated food waste leachate using solvent-based membrane contactor. 61
32203817 2020
29
Proof-of-Concept for Gas-Entrapping Membranes Derived from Water-Loving SiO2/Si/SiO2 Wafers for Green Desalination. 61
32176215 2020
30
Enhancement of Flux Performance in PTFE Membranes for Direct Contact Membrane Distillation. 61
32033433 2020
31
Electrochemical Oxidation-Membrane Distillation Hybrid Process: Utilizing Electric Resistance Heating for Distillation and Membrane Defouling through Thermal Activation of Anodically Formed Persulfate. 61
31934752 2020
32
Mechanism of biofilm formation on a hydrophobic polytetrafluoroethylene membrane during the purification of surface water using direct contact membrane distillation (DCMD), with especial interest in the feed properties. 61
31928216 2020
33
Developing and validating a dynamic model of water production by direct-contact membrane distillation. 61
32208423 2020
34
Analysis of mass transfer behavior in membrane distillation: Mathematical modeling under various conditions. 61
31306977 2019
35
Membrane distillation as post-treatment for anaerobic fluidized bed membrane bioreactor for organic and nitrogen removal. 61
31238271 2019
36
One-step tailoring surface roughness and surface chemistry to prepare superhydrophobic polyvinylidene fluoride (PVDF) membranes for enhanced membrane distillation performances. 61
31200232 2019
37
Combined Osmotic and Membrane Distillation for Concentration of Anthocyanin from Muscadine Pomace. 61
31313316 2019
38
Application of direct contact membrane distillation for saline dairy effluent treatment: performance and fouling analysis. 61
29948689 2019
39
Triple-Layer Nanofiber Membranes for Treating High Salinity Brines Using Direct Contact Membrane Distillation. 61
31064093 2019
40
Slippery for scaling resistance in membrane distillation: A novel porous micropillared superhydrophobic surface. 61
30844676 2019
41
Performance Comparison between Polyvinylidene Fluoride and Polytetrafluoroethylene Hollow Fiber Membranes for Direct Contact Membrane Distillation. 61
30978973 2019
42
Effective treatment of reverse osmosis concentrate from incineration leachate using direct contact membrane distillation coupled with a NaOH/PAM pre-treatment process. 61
30583212 2019
43
Acid mine drainage treatment by integrated submerged membrane distillation-sorption system. 61
30609501 2019
44
Optimization of membrane modification using SiO2 for robust anti-fouling performance with calcium-humic acid feed in membrane distillation. 61
30623884 2019
45
Influence of Hydraulic Pressure on Performance Deterioration of Direct Contact Membrane Distillation (DCMD) Process. 61
30845780 2019
46
Surface Modification of PVDF Membranes for Treating Produced Waters by Direct Contact Membrane Distillation. 61
30813570 2019
47
Experimental Evaluation of the Thermal Polarization in Direct Contact Membrane Distillation Using Electrospun Nanofiber Membranes Doped With Molecular Probes. 61
30759729 2019
48
Evaluating the potential of superhydrophobic nanoporous alumina membranes for direct contact membrane distillation. 61
30199828 2019
49
Influence of dye class on the comparison of direct contact and vacuum membrane distillation applied to remediation of dyeing wastewater. 61
31361190 2019
50
Three-dimensional shape and velocity changes affect responses of a locust visual interneuron to approaching objects. 61
30341087 2018

Variations for Macular Dystrophy, Dominant Cystoid

ClinVar genetic disease variations for Macular Dystrophy, Dominant Cystoid:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 PHF3 , EYS NM_001142800.2(EYS):c.8519A>G (p.Glu2840Gly) SNV Uncertain significance 523415 rs1554163965 GRCh37: 6:64431408-64431408
GRCh38: 6:63721512-63721512

Expression for Macular Dystrophy, Dominant Cystoid

Search GEO for disease gene expression data for Macular Dystrophy, Dominant Cystoid.

Pathways for Macular Dystrophy, Dominant Cystoid

GO Terms for Macular Dystrophy, Dominant Cystoid

Cellular components related to Macular Dystrophy, Dominant Cystoid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell projection GO:0042995 9.8 USH2A TULP1 RPGR RHO RCVRN MAK
2 photoreceptor outer segment GO:0001750 9.5 TULP1 RPGR RHO RCVRN MAK CRB1
3 photoreceptor disc membrane GO:0097381 9.33 RHO PDE6A ABCA4
4 photoreceptor outer segment membrane GO:0042622 9.32 RHO PDE6A
5 photoreceptor inner segment GO:0001917 9.17 USH2A TULP1 RS1 RHO RCVRN MAK

Biological processes related to Macular Dystrophy, Dominant Cystoid according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 retina development in camera-type eye GO:0060041 9.73 TULP1 RPE65 RHO PDE6A NR2E3 CRB1
2 response to stimulus GO:0050896 9.73 USH2A TULP1 RS1 RPGR RPE65 RHO
3 detection of light stimulus involved in visual perception GO:0050908 9.67 TULP1 RPE65 CRB1 BEST1
4 retinoid metabolic process GO:0001523 9.63 RPE65 RHO ABCA4
5 photoreceptor cell maintenance GO:0045494 9.63 USH2A TULP1 RHO MAK CRB1 ABCA4
6 eye photoreceptor cell development GO:0042462 9.62 VEGFA TULP1 NR2E3 CRB1
7 phototransduction GO:0007602 9.58 RHO RCVRN NR2E3
8 cellular response to light stimulus GO:0071482 9.54 RHO CRB1
9 sensory perception of light stimulus GO:0050953 9.52 USH2A RHO
10 retina morphogenesis in camera-type eye GO:0060042 9.51 RPE65 CRB1
11 rhodopsin mediated signaling pathway GO:0016056 9.49 RHO PDE6A
12 phototransduction, visible light GO:0007603 9.48 RHO ABCA4
13 visual perception GO:0007601 9.44 USH2A TULP1 RS1 RPGR RPE65 RHO
14 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.43 VEGFA ACE

Sources for Macular Dystrophy, Dominant Cystoid

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....